Shanghai Hezhou Medicine

Shanghai Hezhou Medicine is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for autoimmune diseases and metabolic disorders. The company's lead candidate, HZ-A-018, is a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical development for atopic dermatitis and alopecia areata. Additionally, Hezhou is advancing HZ-H-101, a thyroid hormone receptor beta (THR-beta) agonist, for the treatment of non-alcoholic steatohepatitis (NASH). Backed by leading venture capital firms like Qiming Venture Partners and TF Capital, the company leverages its internal R&D platform to address significant unmet medical needs. Hezhou Medicine aims to provide high-quality, affordable innovative medicines to patients globally through its robust pipeline of kinase inhibitors and metabolic modulators.